Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes
Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes
复制标题
DOI：
10.1016/j.vaccine.2013.11.048
复制
发表时间：
2014-02-26
期刊：
影响因子：
5.5
通讯作者：
Pinto, Ligia A.
中科院分区：
文献类型：
--
作者：
Alter, Blanche P.;Giri, Neelam;Pinto, Ligia A.
范可尼贫血（FA）和其他遗传性骨髓衰竭综合征（IBMFS）患者发生头颈部鳞状细胞癌和妇科癌的风险极高。在一般人群中，这些部位通常与人乳头瘤病毒（HPV）感染有关，特别是HPV16和HPV18。我们的目的是测量未接种疫苗患者的HPV抗体水平，并确定这些患者在接种了目前许可的HPV L1病毒样颗粒（VLP）疫苗后是否产生并维持与健康女性相似的抗体水平。我们使用HPV16或HPV18 L1 VLP酶联免疫吸收法测定患者血清中的抗hpv IgG抗体水平。除了少数25岁以上的妇女外，大多数未接种疫苗的患者没有检测到抗体水平。FA和其他IBMFS患者在接种疫苗后产生的抗体水平与先前描述的健康女性相似，并且这些水平似乎持续到免疫后5年。因此，FA和其他IBMFS患者对HPV L1 VLP疫苗的抗体反应似乎与一般人群中报道的反应相似，这意味着对疫苗中所含HPV类型的未来感染可能有效。Elsevier Ltd.出版。
Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine. Published by Elsevier Ltd.